What's Happening?
The development of oncology drugs is characterized by compressed timelines due to the urgent needs of patients with limited treatment options. The process from preclinical toxicology to clinical safety is designed to be swift, focusing on generating and
interpreting non-clinical evidence to support first-in-human (FIH) trials. The regulatory framework for oncology drugs, particularly under the ICH S9 guideline, allows for a streamlined set of preclinical studies. These studies are crucial for determining the safety margins and starting doses for clinical trials. The approach involves a 4-week repeat-dose toxicology study in one or two pharmacologically relevant species, with a focus on toxicokinetics to define exposure margins. The process is tailored to balance the pace of development with safety, ensuring that the drugs reach patients quickly without compromising scientific integrity.
Why It's Important?
The streamlined approach to oncology drug development is significant as it addresses the urgent need for new cancer treatments. By focusing on a minimal and targeted non-clinical program, the process reduces the time to reach clinical trials, which is critical for patients with advanced diseases. This method also ensures that the safety and efficacy of new drugs are thoroughly evaluated, minimizing risks to patients. The tailored approach allows for a higher risk-benefit ratio, which is acceptable in oncology due to the severe nature of the diseases being treated. The ability to quickly bring new treatments to market can potentially improve survival rates and quality of life for cancer patients.
